Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21246931 | 0.86 | SRC (0.37) | SRCMAPTLMNAGAAHTT | |
| SCHEMBL15520479 | 0.80 | MAPT (0.33) | SRCMAPTLMNAGAAHTT | |
| SCHEMBL21246839 | 0.78 | KDM4E (0.39) | SRCMAPTLMNAGAAHTT | |
| SCHEMBL15265574 | 0.76 | ALDH1A1 (0.44) | SRCMAPTLMNAGAAHTT | |
| SCHEMBL20898582 | 0.73 | SRC (0.70) | SRCMAPTLMNAGAAHTT | |
| SCHEMBL21246829 | 0.71 | SMN1; SMN2 (0.39) | SRCMAPTLMNAGAAHTT | |
| SCHEMBL22086072 | 0.69 | SRC (0.53) | SRCMAPTLMNAGAAHTT | |
| SCHEMBL25065700 | 0.68 | ABL1 (0.39) | SRCGAAHTTKMT2AALDH1A1 | |
| SCHEMBL20912362 | 0.68 | MAPT (0.50) | SRCMAPTLMNAGAAHTT | |
| SCHEMBL22086527 | 0.68 | ABL1 (0.39) | SRCGAAHTTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2708540-B1 | PYRIMIDO-DIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-9453021-B2 | Pyrimidodiazepinone compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-2708540-A1 | PYRIMIDO-DIAZEPINONE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | REN, AGTR1, KCNJ1 | SRC 3607/4885MAPT 4569/4885LMNA 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.